0.4641
1.11%
+0.0051
After Hours:
.4696
0.0055
+1.19%
23andMe Holding Co stock is currently priced at $0.4641, with a 24-hour trading volume of 2.60M.
It has seen a +1.11% increased in the last 24 hours and a -4.86% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4638 pivot point. If it approaches the $0.4774 resistance level, significant changes may occur.
Previous Close:
$0.459
Open:
$0.455
24h Volume:
2.60M
Market Cap:
$224.12M
Revenue:
$247.99M
Net Income/Loss:
$-521.97M
P/E Ratio:
-0.6446
EPS:
-0.72
Net Cash Flow:
$-194.28M
1W Performance:
-3.89%
1M Performance:
-4.86%
6M Performance:
-37.47%
1Y Performance:
-75.18%
23andMe Holding Co Stock (ME) Company Profile
Name
23andMe Holding Co
Sector
Industry
Phone
650 938 6300
Address
223 North Mathilda Avenue, Sunnyvale
23andMe Holding Co Stock (ME) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-29-22 | Initiated | Berenberg | Buy |
Sep-22-22 | Initiated | Cowen | Outperform |
Nov-15-21 | Downgrade | Citigroup | Buy → Neutral |
Aug-17-21 | Initiated | Credit Suisse | Outperform |
Jul-12-21 | Initiated | Citigroup | Buy |
23andMe Holding Co Stock (ME) Latest News
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
The Motley Fool
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire Inc.
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
The Motley Fool
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
GlobeNewswire Inc.
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock
The Motley Fool
23andMe Holding Co Stock (ME) Financials Data
23andMe Holding Co (ME) Revenue 2024
ME reported a revenue (TTM) of $247.99 million for the quarter ending December 31, 2023, a -19.40% decline year-over-year.
23andMe Holding Co (ME) Net Income 2024
ME net income (TTM) was -$521.97 million for the quarter ending December 31, 2023, a -64.61% decrease year-over-year.
23andMe Holding Co (ME) Cash Flow 2024
ME recorded a free cash flow (TTM) of -$194.28 million for the quarter ending December 31, 2023, a -16.44% decrease year-over-year.
23andMe Holding Co (ME) Earnings per Share 2024
ME earnings per share (TTM) was -$1.11 for the quarter ending December 31, 2023, a -56.34% decline year-over-year.
About 23andMe Holding Co
23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize promising drugs. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. The company was founded in 2006 and is headquartered in Sunnyvale, California.
Cap:
|
Volume (24h):